NASDAQ:ETNB

89bio (ETNB) Stock Forecast, Price & News

$20.45

+0.29 (+1.44%)

(As of 02:41 PM ET)

Compare

Today's Range: $20.00
▼
$20.74
50-Day Range: $14.15
▼
$20.45
52-Week Range: $2.91
▼
$20.85

Volume: 479,633 shs
Average Volume: 1.74 million shs
Market Capitalization: $1.49 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.00

89bio MarketRank™ Forecast

Analyst Rating: Buy
3.14 Rating Score
Upside/Downside: 66.5% Upside
$34.00 Price Target
Short Interest: Healthy
9.91% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.18
Based on 10 Articles This Week
Insider Trading: Acquiring Shares
$41.02 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.92) to ($2.49) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

497th out of 981 stocks

Pharmaceutical Preparations Industry

237th out of 481 stocks

3.6

Analyst's Opinion

Consensus Rating
89bio has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $34.00, 89bio has a forecasted upside of 66.5% from its current price of $20.42.
Amount of Analyst Coverage
89bio has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
9.91% of the outstanding shares of 89bio have been sold short.
Short Interest Ratio / Days to Cover
89bio has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in 89bio has recently decreased by 4.37%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
89bio does not currently pay a dividend.
Dividend Growth
89bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ETNB.

1.8

News and Social Media Coverage

News Sentiment
89bio has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for 89bio this week, compared to 3 articles on an average week.
Search Interest
Only 25 people have searched for ETNB on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added 89bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, 89bio insiders have bought 3,592.96% more of their company's stock than they have sold. Specifically, they have bought $41,016,456.00 in company stock and sold $1,110,666.00 in company stock.
Percentage Held by Insiders
Only 4.40% of the stock of 89bio is held by insiders.
Percentage Held by Institutions
87.78% of the stock of 89bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for 89bio are expected to decrease in the coming year, from ($1.92) to ($2.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of 89bio is -7.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of 89bio is -7.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
89bio has a P/B Ratio of 6.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About 89bio (NASDAQ:ETNB) Stock

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Receive ETNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter.

ETNB Stock News Headlines

June 8, 2023 | americanbankingnews.com

89bio, Inc. (NASDAQ:ETNB) CEO Rohan Palekar Sells 15,000 Shares of Stock

June 8, 2023 | americanbankingnews.com

89bio, Inc. (NASDAQ:ETNB) Director Sells $111,937.50 in Stock

June 8, 2023 | Legacy Research (Affiliate) (Ad)

“One-Stock Millionaire” IGNORES 99.9% of the Market

During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.

June 7, 2023 | finance.yahoo.com

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 7, 2023 | markets.businessinsider.com

SVB Securities Keeps Their Buy Rating on 89bio (ETNB)

June 7, 2023 | finance.yahoo.com

89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023

June 4, 2023 | fool.com

89bio (NASDAQ: ETNB)

June 2, 2023 | americanbankingnews.com

89bio (NASDAQ:ETNB) Stock Price Up 3.3%

June 8, 2023 | Legacy Research (Affiliate) (Ad)

“One-Stock Millionaire” IGNORES 99.9% of the Market

May 29, 2023 | finance.yahoo.com

89BIO (ETNB) Just Overtook the 20-Day Moving Average

May 28, 2023 | seekingalpha.com

89bio: Great Prospects After Excellent Phase 2 Data

May 23, 2023 | finance.yahoo.com

89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

May 18, 2023 | seekingalpha.com

89bio (ETNB) Investor Presentation - Slideshow

May 17, 2023 | americanbankingnews.com

89bio (NASDAQ:ETNB) Reaches New 12-Month High at $18.88

May 15, 2023 | americanbankingnews.com

89bio, Inc. (NASDAQ:ETNB) Receives $32.33 Consensus Target Price from Brokerages

May 14, 2023 | americanbankingnews.com

89bio, Inc. (NASDAQ:ETNB) Insider Sells $247,799.13 in Stock

May 13, 2023 | finance.yahoo.com

Institutional investors are 89bio, Inc.'s (NASDAQ:ETNB) biggest bettors and were rewarded after last week's US$90m market cap gain

May 11, 2023 | msn.com

Oppenheimer Reiterates 89bio (ETNB) Outperform Recommendation

May 10, 2023 | msn.com

HC Wainwright & Co. Maintains 89bio (ETNB) Buy Recommendation

May 10, 2023 | americanbankingnews.com

89bio, Inc. to Post Q2 2023 Earnings of ($0.43) Per Share, HC Wainwright Forecasts (NASDAQ:ETNB)

May 9, 2023 | americanbankingnews.com

HC Wainwright Increases 89bio (NASDAQ:ETNB) Price Target to $35.00

May 8, 2023 | americanbankingnews.com

Cantor Fitzgerald Boosts 89bio (NASDAQ:ETNB) Price Target to $41.00

May 5, 2023 | finance.yahoo.com

Wall Street Analysts Predict a 57.05% Upside in 89BIO (ETNB): Here's What You Should Know

April 22, 2023 | americanbankingnews.com

89bio (NASDAQ:ETNB) Stock Price Down 6.1%

April 20, 2023 | americanbankingnews.com

Brokerages Set 89bio, Inc. (NASDAQ:ETNB) Price Target at $32.22

April 19, 2023 | americanbankingnews.com

Short Interest in 89bio, Inc. (NASDAQ:ETNB) Increases By 44.0%

April 13, 2023 | finance.yahoo.com

Wall Street Analysts See a 79.36% Upside in 89BIO (ETNB): Can the Stock Really Move This High?

See More Headlines

ETNB Price History

30 days | 90 days | 365 days | Advanced Chart

ETNB Company Calendar

Last Earnings: 3/10/2023
Today: 6/08/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ETNB
CUSIP: N/A
CIK: 1785173
Web: www.89bio.com
Phone: 415-432-9270
Fax: N/A
Employees: 41
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $34.00
High Stock Price Forecast: $50.00
Low Stock Price Forecast: $24.00
Forecasted Upside/Downside: +68.7%
Consensus Rating: Buy
Rating Score (0-4): 3.14
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.82)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-102,030,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -50.72%
Return on Assets: -40.53%

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 20.56
Quick Ratio: 20.56

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.00 per share
Price / Book: 6.72

Miscellaneous

Outstanding Shares: 72,870,000
Free Float: 69,662,000
Market Cap: $1.47 billion
Optionable: Not Optionable
Beta: 0.76

Key Executives

Mr. Rohan Palekar (Age 56)
CEO & Director
Comp: $829.41k

Mr. Quoc Le-Nguyen (Age 54)
Chief Technical Operations Officer & Head of Quality
Comp: $571.12k

Dr. Harry Mansbach M.D. (Age 57)
Chief Medical Officer
Comp: $603.22k

Mr. Ryan Stephen Martins (Age 44)
Chief Financial Officer

Mr. Shiva K. Natarajan (Age 56)
Sr. VP of Fin. & Principal Accounting Officer

Ms. Melissa Abel
Sr. VP of Commercial Strategy & Communications

Ms. Amanda Hill
VP of People & Culture

Ms. Yun Bai
VP & Head of CMC

Mr. Paul Shin
Sr. VP of R&D Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ETNB Stock - Frequently Asked Questions

Should I buy or sell 89bio stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ETNB shares.
View ETNB analyst ratings or view top-rated stocks.
What is 89bio's stock price forecast for 2023?: 7 analysts have issued 12-month price objectives for 89bio's shares. Their ETNB share price forecasts range from $24.00 to $50.00. On average, they expect the company's share price to reach $34.00 in the next twelve months. This suggests a possible upside of 68.7% from the stock's current price.
View analysts price targets for ETNB or view top-rated stocks among Wall Street analysts.
How have ETNB shares performed in 2023?: 89bio's stock was trading at $12.73 on January 1st, 2023. Since then, ETNB shares have increased by 58.4% and is now trading at $20.16.
View the best growth stocks for 2023 here.
When is 89bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ETNB earnings forecast.
How were 89bio's earnings last quarter?: 89bio, Inc. (NASDAQ:ETNB) posted its quarterly earnings results on Friday, March, 10th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.15.
What ETFs hold 89bio's stock?: ETFs with the largest weight of 89bio (NASDAQ:ETNB) stock in their portfolio include AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), SPDR S&P Biotech ETF (XBI), Invesco Raymond James SB-1 Equity ETF (RYJ), Harbor Health Care ETF (MEDI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), ALPS Medical Breakthroughs ETF (SBIO), Harbor Disruptive Innovation ETF (INNO) and Invesco Nasdaq Biotechnology ETF (IBBQ).

What other stocks do shareholders of 89bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), Raytheon Technologies (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO).
When did 89bio IPO?: (ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.
What is 89bio's stock symbol?: 89bio trades on the NASDAQ under the ticker symbol "ETNB."
Who are 89bio's major shareholders?: 89bio's stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (4.21%), Federated Hermes Inc. (3.49%), Suvretta Capital Management LLC (3.03%), Boxer Capital LLC (2.88%), BVF Inc. IL (2.53%) and BlackRock Inc. (1.71%). Insiders that own company stock include Edward Morrow Atkinson III, Gregory Grunberg, Longitude Capital Partners Iii, Michael R Hayden, Ollin B Sykes, Orbimed Advisors Llc, Quoc Le-Nguyen, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins.
View institutional ownership trends.
How do I buy shares of 89bio?: Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is 89bio's stock price today?: One share of ETNB stock can currently be purchased for approximately $20.16.
How much money does 89bio make?: 89bio (NASDAQ:ETNB) has a market capitalization of $1.47 billion. The company earns $-102,030,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis.
How can I contact 89bio?: 89bio's mailing address is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. The official website for the company is www.89bio.com. The company can be reached via phone at 415-432-9270 or via email at investors@89bio.com.

This page (NASDAQ:ETNB) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial